Allergy & Mast Cell Conditions

Understanding Mast Cell and Allergic Conditions

Mast cells are immune cells that release histamine and over 200 other inflammatory mediators when activated. In healthy individuals, this response is appropriate and limited. In mast cell and allergic conditions, this response becomes dysregulated — either through excessive activation, abnormal proliferation, or antibody-driven sensitization.

The common denominator in these conditions is an overabundance of circulating inflammatory mediators, IgE antibodies, and immune complexes in the blood plasma — factors that can be physically removed through therapeutic plasma exchange.

Mast Cell Activation Syndrome (MCAS)

MCAS is a condition where mast cells throughout the body become inappropriately activated, releasing cascades of inflammatory mediators that can affect virtually every organ system. Symptoms are often chronic, fluctuating, and multi-systemic:

• Skin: flushing, hives, angioedema, itching
• GI: nausea, cramping, diarrhea, food intolerances
• Cardiovascular: tachycardia, blood pressure instability, presyncope
• Neurological: brain fog, headaches, anxiety, nerve pain
• Respiratory: throat tightening, shortness of breath, nasal congestion
• Systemic: fatigue, temperature dysregulation, anaphylactoid episodes

How TPE May Help MCAS

While TPE cannot prevent mast cell activation, it can reduce the downstream consequences:

• IgE reduction — Many MCAS patients have elevated total or specific IgE that sensitizes mast cells. Reducing IgE lowers the trigger sensitivity.
• Mediator clearance — Histamine, tryptase, prostaglandins, and other mast cell mediators circulating in plasma are physically removed.
• Autoantibody removal — A subset of MCAS patients have autoantibodies against IgE receptors that trigger mast cell degranulation. Removing these antibodies may reduce activation frequency.
• Immune complex clearance — Circulating immune complexes can trigger mast cell activation via Fc receptors.

Evidence for TPE in MCAS

Case reports and small series have documented improvement in MCAS symptoms following TPE, particularly in patients who:

• Have documented elevated IgE or anti-FcεRI autoantibodies
• Experience symptoms primarily driven by circulating mediators (rather than fixed tissue mast cells)
• Have not responded adequately to multiple mast cell stabilizers and antihistamines

This is an emerging indication without large randomized trials. However, the mechanistic rationale is sound given the known plasma components driving mast cell activation.

Chronic Urticaria (Chronic Hives)

Chronic spontaneous urticaria (CSU) involves recurrent hives and/or angioedema lasting 6 weeks or longer, often without an identifiable external trigger. It affects approximately 1% of the population and can persist for years.

The Autoimmune Subtype

In approximately 30-50% of chronic urticaria patients, the condition is driven by autoantibodies:

• Anti-FcεRI antibodies — Antibodies that bind to the IgE receptor on mast cells, triggering degranulation
• Anti-IgE antibodies — Antibodies that cross-link IgE on mast cells, causing histamine release
• Thyroid autoantibodies — Frequently coexist and may contribute to mast cell activation

These patients test positive on autologous serum skin testing (ASST) — injecting their own serum causes a wheal, demonstrating that something in their blood triggers mast cell activation.

TPE for Chronic Urticaria

For autoimmune chronic urticaria refractory to:

• High-dose antihistamines (up to 4x standard dosing)
• Omalizumab (anti-IgE therapy)
• Cyclosporine or other immunosuppressants

TPE offers a pathway to directly remove the causative autoantibodies and IgE from circulation. Case series have reported:

• Rapid clearing of hives within 24-48 hours of exchange
• Sustained benefit when combined with ongoing immunomodulation
• Particular effectiveness in ASST-positive patients

Evidence Level

TPE for chronic urticaria is supported by multiple case series and is listed in ASFA guidelines as a Category III indication (optimum role of TPE not established; individualized decision). It is most appropriate for severe, treatment-refractory cases with demonstrated autoimmune etiology.

Severe Allergies

In severe allergic conditions — particularly those involving extremely high IgE levels or multiple life-threatening sensitivities — TPE may be considered as part of a comprehensive approach:

High IgE Syndromes

• Patients with markedly elevated total IgE (often >1000 IU/mL) may have enhanced anaphylaxis risk
• TPE can reduce circulating IgE levels, potentially lowering sensitization of mast cells and basophils
• May be used prior to immunotherapy initiation in highly sensitized patients

Refractory Anaphylaxis

• Patients with recurrent idiopathic anaphylaxis despite avoidance and prophylaxis
• Removal of IgE and potential autoantibody triggers
• Bridge therapy while longer-term immune modulation takes effect

Evidence Level

TPE for severe allergies is supported primarily by case reports and mechanistic reasoning. It is most applicable in severe, life-threatening situations where standard allergy management has been insufficient.

What TPE Can and Cannot Do

TPE can:

• Remove 60-70% of circulating IgE in a single exchange
• Clear histamine, tryptase, and other inflammatory mediators from plasma
• Remove autoantibodies that trigger mast cell degranulation
• Provide rapid (hours to days) reduction in circulating inflammatory burden

TPE cannot:

• Stop mast cells from producing new mediators
• Cure the underlying mast cell disorder
• Replace daily medications (antihistamines, mast cell stabilizers)
• Prevent future IgE production (antibodies regenerate over weeks)

Our Approach

Our board-certified physician will evaluate the condition thoroughly with you and you will make an informed decision.

Next Steps

If you have MCAS, chronic hives, or severe allergies that have not responded adequately to standard treatments, request a consultation to discuss whether TPE could be a beneficial addition to your treatment plan. Laboratory results (total IgE, tryptase, autoantibody panels) are helpful to bring to your appointment.